---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000273"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2026-01-15T23:59:59+00:00"
generated_at: "2026-05-16T10:08:31.617326+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mount Sinai treats first prostate cancer patient with Profound's TULSA-PRO system

## Summary
- Mount Sinai Hospital (ranked #6 for Urology) is first in Metro New York to offer TULSA-PRO incision-free, MRI-guided prostate treatment.
- Procedure uses AI-powered, directional ultrasound from inside urethra to heat tissue to 55-57°C while protecting nerves; no blood loss or overnight stay.
- Patient discharged same day; initial treatment outcome positive.
- Profound CEO Arun Menawat noted collaboration between Urology and Interventional Radiology at Mount Sinai.

## SEC filing metadata
- accession: 0001171843-26-000273
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2026-01-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184326000273/0001171843-26-000273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184326000273/f8k_011526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000273
- JSON: https://secwatch.observer/filing/0001171843-26-000273.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.